Abstract: An antibody that binds to the PD-L1 protein or CD137 protein, an antigen-binding fragment or a variant thereof, as well as a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. The bispecific antibody has a strong ability to specifically recognize the PD-L1 protein and the CD137 protein, and can enhance T-cell activity. The antibody or the antigen-binding fragment or the variant thereof and the bispecific antibody may be used in the prevention and treatment of tumors.

Abstract: An isolated antigen binding protein capable of targeting MSLN. The isolated antigen binding protein comprises at least one CDR in an antibody heavy chain variable region VH, and the VH comprises an amino acid sequence as set forth in any one of SEQ ID NO: 8, SEQ ID NO: 13, SEQ ID NO: 69, and SEQ ID NO: 70. Also provided are a chimeric antigen receptor comprising the antigen binding protein, and use of the antigen binding protein in treating tumors.

Abstract: Provided is a cell, comprising and/or expressing a chimeric antigen receptor targeting claudin 18.2 (CLDN18.2), and a chimeric antigen receptor targeting mesothelin (MSLN) protein. Also provided is an expression vector, comprising a nucleic acid sequence which encodes the chimeric antigen receptor targeting CLDN18.2 and a nucleic acid sequence which encodes the chimeric antigen receptor targeting MSLN. Also provided are a preparation method for and a use of the cell and/or the expression vector.

Abstract: The present application relates to a chimeric antigen receptor, comprising a first antigen binding domain and a second antigen binding domain. The first antigen binding domain targets a G protein-coupled receptor class C group 5 member D (GPRC5D) protein, and the second antigen binding domain targets the GPRC5D protein. The present application further provides a cell comprising the chimeric antigen receptor and use thereof.

Abstract: Disclosed is a method for promoting immune cell proliferation. The method comprises the following step: upregulating the expression of low-density lipoprotein receptor-related proteins or fragments thereof in immune cells.

Abstract: A chimeric antigen receptor (CAR), containing a BCMA (B cell maturation antigen) binding domain. The BCMA binding domain includes an antibody or an antigen-binding fragment of an antibody that specifically binds to BCMA. The antibody contains a heavy-chain complementarity determining region 3 (HCDR3), a heavy-chain complementarity determining region 2 (HCDR2), and a heavy-chain complementarity determining region 1 (HCDR1). The HCDR3 contains an amino acid sequence as set forth in SEQ ID NO: 25, the HCDR2 contains an amino acid sequence as set forth in SEQ ID NO: 41, and the HCDR1 contains an amino acid sequence as set forth in SEQ ID NO: 21.

Abstract: An isolated antigen binding protein capable of binding to a G protein-coupled receptor, class C, group 5, member D (GPRCSD) protein with an EC50 value of 1.0 ?g/mL is described. A chimeric antigen receptor comprising the isolated antigen binding protein and its use in the treatment of tumors is also described.

Abstract: The present application relates to a chimeric antigen receptor (CAR), comprising a GPC3 binding domain, a transmembrane domain, a costimulatory domain and an intracellular signaling domain, the GPC3 binding domain comprises an antibody or a fragment thereof which specifically binding to GPC3, the antibody comprises a light chain complementary determining region 1 (LCDR1), a light chain complementary determining region 2 (LCDR2) and a light chain complementary determining region 3 (LCDR3), the amino acid sequence of the LCDR1 is as set forth in SEQ ID NO: 16, the amino acid sequence of the LCDR2 is as set forth in SEQ ID NO: 17 and the amino acid sequence of the LCDR3 is as set forth in SEQ ID NO: 18. The present application also relates to an isolated nucleic acid encoding the CAR, a vector comprising the nucleic acid, an immune effector cell comprising the nucleic acid or the vector and a preparation method thereof as well as a use of the CAR.

Abstract: An antibody that binds to the PD-L1 protein or CD137 protein, an antigen-binding fragment or a variant thereof, as well as a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. The bispecific antibody has a strong ability to specifically recognize the PD-L1 protein and the CD137 protein, and can enhance T-cell activity. The antibody or the antigen-binding fragment or the variant thereof and the bispecific antibody may be used in the prevention and treatment of tumors.

Abstract: Provided are an antibody that binds to the PD-L1 protein or CD137 protein, an antigen-binding fragment or a variant thereof, as well as a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. The bispecific antibody has a strong ability to specifically recognize the PD-L1 protein and the CD137 protein, and can enhance T-cell activity. Also provided is the use of the antibody or the antigen-binding fragment or the variant thereof and the bispecific antibody in the prevention and treatment of tumors.

Abstract: Disclosed is a method for promoting immune cell proliferation. The method comprises the following step: upregulating the expression of low-density lipoprotein receptor-related proteins or fragments thereof in immune cells.

Abstract: An isolated antigen-binding protein may be capable of binding to CLDN18.2. Such an isolated antigen-binding protein may include HCDR1, HCDR2, and/or HCDR3. The HCDR1 may include an amino acid sequence as set forth in any one of SEQ ID NO: 2, SEQ ID NO: 10, and SEQ ID NO: 16. The HCDR2 may include an amino acid sequence as set forth in SEQ ID NO: 68 or SEQ ID NO: 11. The HCDR3 may include an amino acid sequence as set forth in SEQ ID NO: 67. A chimeric antigen receptor may include the isolated antigen binding protein. A method may make such an antigen-binding protein and an antigen binding protein and the chimeric antigen receptor may be derived from the isolated antigen-binding protein.

Abstract: An antibody that binds to the PD-L1 protein or CD137 protein, an antigen-binding fragment or a variant thereof, as well as a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. The bispecific antibody has a strong ability to specifically recognize the PD-L1 protein and the CD137 protein, and can enhance T-cell activity. The antibody or the antigen-binding fragment or the variant thereof and the bispecific antibody may be used in the prevention and treatment of tumors.

Abstract: The present invention discloses a preparation and a method for improving ring rot resistance of apple fruits and belongs to the technical field of plant disease resistance. Resistance of apple fruits to ring rot may be significantly improved by soaking the fruits with a sorbitol solution. Moreover, the sorbitol solution is effective to multiple varieties; the barrier in control of ring rot through chemical pesticides and the like may be overcome; and pollution of the pesticides and the like to the ecological environment is greatly decreased, thereby decreasing losses caused by occurrence of apple ring rot in a maturation period or a storage period.

Abstract: Provided is a modified immune cell, comprising a chimeric antigen receptor and/or a coding element therefor, or comprising a T cell receptor and/or a coding element therefor. The immune cell further comprises: leptin and/or a functional fragment thereof; and/or, a leptin receptor and/or a functional fragment thereof, and the expression quantity of the leptin receptor and/or the functional fragment thereof in the immune cell is increased compared with that in an immune cell without the corresponding modification. In addition, also provided is another modified immune cell, comprising leptin and/or a functional fragment thereof, and/or, a leptin receptor and/or a functional fragment thereof, and a low-density lipoprotein-receptor-related protein or a fragment thereof.

Abstract: An antibody that binds to the PD-L1 protein or CD137 protein, an antigen-binding fragment or a variant thereof, as well as a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. The bispecific antibody has a strong ability to specifically recognize the PD-L1 protein and the CD137 protein, and can enhance T-cell activity. The antibody or the antigen-binding fragment or the variant thereof and the bispecific antibody may be used in the prevention and treatment of tumors.

Abstract: Provided are an antibody that binds to the PD-L1 protein or CD137 protein, an antigen-binding fragment or a variant thereof, as well as a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. The bispecific antibody has a strong ability to specifically recognize the PD-L1 protein and the CD137 protein, and can enhance T-cell activity. Also provided is the use of the antibody or the antigen-binding fragment or the variant thereof and the bispecific antibody in the prevention and treatment of tumors.

Abstract: Disclosed is a method for promoting immune cell proliferation. The method comprises the following step: upregulating the expression of low-density lipoprotein receptor-related proteins or fragments thereof in immune cells.

Abstract: Provided are techniques for generating a relational query. Information is collected from a query specification and a model for an On-Line Analytical Processing (OLAP) query having at least a first expression and a second expression. The collected information is used to generate a relational query to retrieve report data to be used to satisfy the first expression and the second expression.

Abstract: Provided are techniques for generating a relational query. Information is collected from a query specification and a model for an On-Line Analytical Processing (OLAP) query having at least a first expression and a second expression. The collected information is used to generate a relational query to retrieve report data to be used to satisfy the first expression and the second expression.